Marché mondial de l’hépatite E – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché de l'hépatite E

Le marché de l'hépatite E devrait connaître une croissance significative au cours de la période de prévision. Les marchés émergents et les investissements massifs dans la recherche et le développement sont les facteurs responsables de la croissance de ce marché. La croissance du marché de l'hépatite E a été renforcée par l'augmentation des cas d'hépatite E et l'augmentation des activités de recherche et développement menées par de nombreuses sociétés pharmaceutiques. En outre, les progrès dans les options de traitement et la présence d'établissements de santé bien établis sont quelques-uns des facteurs qui influent sur la demande du marché de l'hépatite E. Le COVID-19 a également eu un impact majeur sur la croissance du marché.

Data Bridge Market Research analyse le taux de croissance du marché mondial de l'hépatite E au cours de la période de prévision 2022-2029. Le marché de l'hépatite E a tendance à avoir un TCAC sain au cours de la période de prévision mentionnée. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe Data Bridge Market Research comprend également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché de l'hépatite E

Market Definition

Hepatitis E, also known as hepatitis E virus (HEV), is a viral liver inflammation disease. This virus is spread primarily by faecal-oral transmission and contaminated food and water. Although hepatitis E virus often causes acute and self-limiting infection as virus usually does not take too long-term illness and resolves itself. However, immunocompromised patients can lead to life-threatening conditions or even death.   

Global Hepatitis E Market Dynamics

Drivers

• Prevalence of Hepatitis E

According to World Health Organizations in July 2020, each year there is an estimated 20 million Hepatitis E infections worldwide which leads to a 3.3 million symptomatic cases of hepatitis E. Thus, it boosts the market growth.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Increasing Demand for Retail Pharmacies

Rise in the number of hepatitis E therapeutics being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

• Increase in Geriatric Population

The geriatric population is expected to increase the patient population globally, which boots the global hepatitis E market in the forecast period. According to the WHO, the global elderly population is expected to reach around 2 billion by 2050 from 617 million in 2015. This boost the market growth.

 Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global hepatitis E market over a forecast period.

• High Cost

The huge expenditure associated with Hepatitis E treatment medications surely hamper the market growth.

This global hepatitis E market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hepatitis E market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Hepatitis E Market            

Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials. The unavailability of the specific COVID-19 tests presented positive opportunities for the manufacturers to introduce their COVID-19 diagnostic kits. Many major market players as well as many start-ups from several countries are gathering up to boost the market growth.

Global Hepatitis E Market Scope

The global hepatitis E market is segmented on the basis of drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Antiviral Drugs
• Interferons
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Hepatitis E Market Regional Analysis/Insights

The global hepatitis E market is analysed and market size insights and trends are provided by drug class, distribution channel and end-user as referenced above.

The major countries covered in the global hepatitis E market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global hepatitis E market throughout the forecasted period due to the high prevalence of hepatitis E, high diagnostic rate and presence of sophisticated medical facilities in order to optimize the treatment for patient suffering from the hepatitis E.

Asia-Pacific dominates the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Analyse du paysage concurrentiel et des parts de marché mondiales de l'hépatite E

Le paysage concurrentiel du marché mondial de l'hépatite E fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché mondial de l'hépatite E.

Les principaux acteurs opérant sur le marché mondial de l'hépatite E comprennent :

• Pfizer Inc. (États-Unis)
• GSK plc (Royaume-Uni)
• Novartis SA (Suisse)
• Mylan NV (États-Unis)
• Teva Pharmaceutical Industries Ltd. (Israël)
• Sanofi (France)
• Boehringer Ingelheim International GmbH. (Allemagne)
• AstraZeneca (Royaume-Uni)
• Johnson & Johnson Private Limited (États-Unis)
• Bayer AG (Allemagne)
• Merck & Co., Inc. (États-Unis)
• F. Hoffmann-La Roche SA (Suisse)
• Société Bristol-Myers Squibb (États-Unis)
• Cadila Pharmaceuticals (Inde)

SKU-53752